Valuation: FamiCord AG

Market Cap 63.28M 72.42M 58.11M 54.19M 103M 6.89B 104M 700M 271M 3.38B 272M 266M 11.65B P/E 2026 *
363x
P/E 2027 * 60.5x
Enterprise Value 71.28M 81.57M 65.45M 61.04M 116M 7.77B 118M 788M 305M 3.81B 306M 300M 13.12B EV / Sales 2026 *
0.84x
EV / Sales 2027 * 0.78x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 day-17.75%
1 week+8.10%
Current month+14.29%
1 month+8.94%
3 months-12.62%
6 months-32.35%
Current year-32.35%
1 week 3.58
Extreme 3.58
4.19
1 month 3.58
Extreme 3.58
4.19
Current year 3.58
Extreme 3.58
6.1
1 year 3.58
Extreme 3.58
9.8
3 years 3.58
Extreme 3.58
9.8
5 years 3.58
Extreme 3.58
16.49
10 years 3.58
Extreme 3.58
17.04
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2022
Director of Finance/CFO 53 01/08/2024
Chief Tech/Sci/R&D Officer - 01/03/2025
Director TitleAgeSince
Chairman 62 28/06/2017
Director/Board Member - 01/01/2017
Director/Board Member 54 01/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-17.75%+8.10% - - 72.42M
-0.09%+0.06%+57.24%+51.48% 134B
+4.39%+6.09%+8.59%+35.26% 91.07B
+0.21%+6.08%-0.35%+62.96% 27.15B
-0.14%+4.60%+22.15%+53.47% 23.88B
-0.83%+0.14%-21.29%-26.68% 19.96B
+6.55%+10.75%+18.29%+150.33% 17.55B
+1.46%+2.84%+2.13%+7.93% 15.02B
+3.02%+10.10%+64.78%+133.81% 15.08B
-0.55%+0.15%-14.54%-6.28% 12.65B
Average -0.37%+4.50%+15.22%+51.37% 39.55B
Weighted average by Cap. +1.54%+3.39%+27.17%+48.43%

Financials

2026 *2027 *
Net sales 85M 97.28M 78.05M 72.79M 138M 9.26B 140M 940M 364M 4.54B 365M 357M 15.65B 88.4M 101M 81.18M 75.7M 144M 9.63B 146M 977M 379M 4.72B 380M 372M 16.28B
Net income 300K 343K 275K 257K 487K 32.68M 495K 3.32M 1.29M 16.03M 1.29M 1.26M 55.24M 1M 1.14M 918K 856K 1.62M 109M 1.65M 11.06M 4.28M 53.44M 4.3M 4.2M 184M
Net Debt 8M 9.16M 7.35M 6.85M 12.99M 872M 13.21M 88.45M 34.28M 428M 34.38M 33.63M 1.47B 6M 6.87M 5.51M 5.14M 9.74M 654M 9.91M 66.34M 25.71M 321M 25.78M 25.22M 1.1B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
723
Date Price Change Volume
25/10/24 4.194 -66.71% 600
02/07/26 €3.630 -1.09% 7
01/07/26 €3.670 0.00% 110
30/06/26 €3.670 -2.39% 8
29/06/26 €3.760 -3.09% 1
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.630EUR
Average target price
6.500EUR
Spread / Average Target
+79.06%

Annual profits - Rate of surprise